Hansa Biopharma 2022 SEB Nordic Healthcare Seminar Investor Presentation

Hansa Biopharma presented its investor overview at the SEB Nordic Healthcare Seminar in January 2022, highlighting the European approval of Idefirix for kidney transplantation in highly sensitized patients. The presentation covers the company's validated technology platform, clinical pipeline in transplantation and autoimmune diseases, and financial position with funding secured into 2023.